Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heart Failure Society Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

Rheos diastolic heart failure trial: Minneapolis firm CVRx has begun a 60-patient randomized, double-blind clinical trial of its Rheos baroreflex activation therapy system for treatment of diastolic heart failure, a heart's inability to fully relax and let the ventricle fill with blood, Michael Zile, Medical University of South Carolina, Charleston, said at the Heart Failure Society of America Scientific Meeting in Toronto on Sept. 22. Rheos electrically activates the carotid baroreceptors, the body's natural cardiovascular regulation sensor. All patients in the trial will have heart failure with a left-ventricular ejection fraction of at least 45%. The primary endpoint of the trial will be left-ventricular mass index. The Minneapolis company is also currently sponsoring a 300-patient trial of Rheos to treat drug-resistant hypertension (1"The Gray Sheet" Aug. 4, 2008, p. 14)
Advertisement

Related Content

Hypertension Device Trials, DES Cost Data Headline ACC 2009 In Orlando
Hypertension Device Trials, DES Cost Data Headline ACC 2009 In Orlando
Hypertension Device Trials, DES Cost Data Headline ACC 2009 In Orlando
Financings In Brief
Financings In Brief
Advertisement
UsernamePublicRestriction

Register

MT026616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel